Rapirosiran
Rapirosiran (ALN-HSD) is a HSD17β13-targeting siRNA. Rapirosiran can be used for the research of metabolic dysfunction-associated steatohepatitis.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- CAS 番号: 2755196-97-3
- 分子量:16307.22
-
保管条件:
Please store the product under the recommended conditions in the Certificate of Analysis.
17β-HSD アイソフォーム固有の製品をすべて表示
More
生物活性
Rapirosiran can silence HSD17β13 in the liver, thereby reducing free fatty acid levels[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
化学情報
-
CAS 番号 2755196-97-3
-
分子量 16307.22
-
SMILES
[Rapirosiran]
-
別名
ALN-HSD; ALN-288996; AD-288996
-
輸送条件
Room temperature in continental US; may vary elsewhere.
-
保管条件
Please store the product under the recommended conditions in the Certificate of Analysis.
純度とドキュメンテーション
参考文献
Calculators
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)
- Rapirosiran
- 2755196-97-3
- ALN-HSD
- ALN-288996
- AD-288996
- ALN288996
- ALN 288996
- ALN-288996
- AD288996
- AD 288996
- AD-288996
- 17β-HSD
- Small Interfering RNA (siRNA)
- ESC-GalNAc-conjugated agent
- metabolic dysfunction-associated steatohepatitis
- non-alcoholic steatohepatitis
- hepatic HSD17β13 mRNA
- HSD17β13
- NASH patients
- healthy adults
- Inhibitor
- inhibitor
- inhibit